Jude Canon
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Lung Cancer Research Studies, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity(2019)2,187 cited
- → KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors(2020)1,646 cited
- → Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors(2019)690 cited
- → AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies(2018)409 cited
- → Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development(2014)291 cited
- → AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer(2020)224 cited
- → Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis(2007)209 cited
- → Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction(2012)167 cited
- → The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents(2015)145 cited
- → Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release(2019)123 cited